Jagannathan, Prasanna http://orcid.org/0000-0001-6305-758X
Andrews, Jason R.
Bonilla, Hector
Hedlin, Haley http://orcid.org/0000-0002-0757-7959
Jacobson, Karen B.
Balasubramanian, Vidhya
Purington, Natasha
Kamble, Savita
de Vries, Christiaan R. http://orcid.org/0000-0002-4667-5973
Quintero, Orlando
Feng, Kent http://orcid.org/0000-0002-7949-9531
Ley, Catherine
Winslow, Dean
Newberry, Jennifer
Edwards, Karlie
Hislop, Colin
Choong, Ingrid
Maldonado, Yvonne
Glenn, Jeffrey
Bhatt, Ami http://orcid.org/0000-0001-8099-2975
Blish, Catherine http://orcid.org/0000-0001-6946-7627
Wang, Taia http://orcid.org/0000-0002-3894-685X
Khosla, Chaitan
Pinsky, Benjamin A. http://orcid.org/0000-0001-8751-4810
Desai, Manisha
Parsonnet, Julie http://orcid.org/0000-0001-7342-5366
Singh, Upinder
Funding for this research was provided by:
SU | School of Medicine, Stanford University (Anonymous Donors)
Article History
Received: 22 December 2020
Accepted: 3 March 2021
First Online: 30 March 2021
Competing interests
: C.H. and I.C. are scientists at Eiger BioPharmaceuticals, Inc., which provided the Interferon Lambda used for this study. J.G. serves on the board of Eiger BioPharmaceuticals, Inc. C.H. and I.C. own stock and options of Eiger BioPharmaceuticals, Inc. J.G. has an equity interest in Eiger BioPharmaceuticals, Inc. J.G. and I.C. are inventors on a pending patent application relating to the use of interferon lambda for coronavirus. Eiger BioPharmaceuticals played no role in study design, conduct of the study, or analysis of the data. All other authors declare no competing interests.